Possible applications for replicating HIV 1 vectors.

HIV therapy Pub Date : 2010-05-01 DOI:10.2217/hiv.10.20
Atze T Das, Rienk E Jeeninga, Ben Berkhout
{"title":"Possible applications for replicating HIV 1 vectors.","authors":"Atze T Das,&nbsp;Rienk E Jeeninga,&nbsp;Ben Berkhout","doi":"10.2217/hiv.10.20","DOIUrl":null,"url":null,"abstract":"<p><p>Since its discovery some 25 years ago, much has been learned about HIV type 1 and the molecular details of its replication cycle. This insight has been used to develop lentiviral vector systems that have advantages over conventional retroviral vector systems. For safety reasons, the lentiviral vector systems are replication incompetent and the risk of generating a replication competent virus has been minimized. Nevertheless, there may be certain applications for replication competent HIV based vector systems, and we will review our activities in this particular field. This includes the generation of a conditionally replicating HIV 1 variant as a safe live attenuated virus vaccine, the construction of mini HIV variants as cancer selective viruses for virotherapy against leukemia, and the use of a conditionally live anti HIV gene therapy vector. Although safety concerns will undoubtedly remain for the use of replication competent HIV based vector systems, some of the results in cell culture systems are very promising and warrant further testing in appropriate animal models.</p>","PeriodicalId":88510,"journal":{"name":"HIV therapy","volume":"4 3","pages":"361-369"},"PeriodicalIF":0.0000,"publicationDate":"2010-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/hiv.10.20","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"HIV therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/hiv.10.20","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 6

Abstract

Since its discovery some 25 years ago, much has been learned about HIV type 1 and the molecular details of its replication cycle. This insight has been used to develop lentiviral vector systems that have advantages over conventional retroviral vector systems. For safety reasons, the lentiviral vector systems are replication incompetent and the risk of generating a replication competent virus has been minimized. Nevertheless, there may be certain applications for replication competent HIV based vector systems, and we will review our activities in this particular field. This includes the generation of a conditionally replicating HIV 1 variant as a safe live attenuated virus vaccine, the construction of mini HIV variants as cancer selective viruses for virotherapy against leukemia, and the use of a conditionally live anti HIV gene therapy vector. Although safety concerns will undoubtedly remain for the use of replication competent HIV based vector systems, some of the results in cell culture systems are very promising and warrant further testing in appropriate animal models.

Abstract Image

复制HIV 1载体的可能应用。
自从它在25年前被发现以来,人们对1型艾滋病毒及其复制周期的分子细节已经了解了很多。这一见解已被用于开发慢病毒载体系统,它比传统的逆转录病毒载体系统有优势。出于安全考虑,慢病毒载体系统是不具备复制能力的,产生具有复制能力的病毒的风险已经降到最低。尽管如此,基于HIV的载体系统可能会有一些复制能力的应用,我们将回顾我们在这一特定领域的活动。这包括产生有条件复制的HIV 1变异作为安全的减毒活疫苗,构建迷你HIV变异作为白血病病毒治疗的癌症选择性病毒,以及使用有条件活的抗HIV基因治疗载体。尽管使用具有复制能力的HIV载体系统无疑仍存在安全问题,但细胞培养系统的一些结果非常有希望,值得在适当的动物模型中进一步测试。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信